Vernalis buys Ionix Pharmaceuticals
Executive Summary
Vernalis PLC (develops drugs for neurological disorders and cancer) has acquired privately held analgesic drug company Ionix Pharmaceuticals Ltd. in a stock swap worth about £12mm ($21mm), plus a potential earnout of £5mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice